In addition to focusing on new games, 180 plans to maintain its current portfolio of biotech intellectual property. The Company actively seeks opportunities to maximize the value of its biotechnology assets through a variety of corporate transactions, including joint ventures, partnerships and outright sales. Management remains committed to optimizing the value of all assets for the benefit of shareholders. We would like to highlight the latest research results regarding our synthetic CBD analogs, which are artificial derivatives of cannabidiol. 180 aims to develop a true alternative to SCA, or unregulated CBD, that is safe, non-psychoactive, and formulated for increased efficacy and bioavailability. 180 previously published the results of a study comparing two new tablet forms of CBD with Epidiolex, a U.S. Food and Drug Administration (FDA)-approved liquid CBD medication. The study involved 12 participants, and one of the pills absorbed CBD faster and reached higher levels in the body than Epidiolex, while the other pill was similar to Epidiolex. It turns out that there is something. Both tablet forms were well tolerated. CBD has been found to be effective in treating conditions such as epilepsy, inflammation, PTSD, and pain in certain studies, but it is typically taken as a liquid, which can lead to erratic absorption. A new tablet shape developed with 'ProNanoLipospheres' technology aims to solve this problem by improving uptake. These results suggest that solid CBD tablets could provide a more reliable and convenient option for patients and could have significant commercial benefits in the future. .
